UPLOAD Filing
Monte Rosa Therapeutics, Inc.
Date: Aug. 21, 2025 · CIK: 0001826457 · Accession: 0000000000-25-008933
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-40522
Letter
Re: Monte Rosa Therapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2024 Filed March 20, 2025 File No. 001-40522 Dear Edmund Dunn:
August 21, 2025
Edmund Dunn SVP, Corporate Controller Monte Rosa Therapeutics, Inc. 321 Harrison Avenue, Suite 900 Boston, Massachusetts 02118
We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation
Finance
Office of Life Sciences
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> August 21, 2025 Edmund Dunn SVP, Corporate Controller Monte Rosa Therapeutics, Inc. 321 Harrison Avenue, Suite 900 Boston, Massachusetts 02118 Re: Monte Rosa Therapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2024 Filed March 20, 2025 File No. 001-40522 Dear Edmund Dunn: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences </TEXT> </DOCUMENT>